Antidiabetic AgentsPrandin (repaglinide) Tablets
Manufacturer: Novo Nordisk
Drug Approval Classification: Supplemental New Drug Application (Approval Date: 09/01/03)
Precautions/Drug Interaction: Results of a pharmacokinetic drug-drug interaction study of Prandin (repaglinide) and Lopid (gemfibrozil) found that concomitant use may result in enhanced and prolonged glucose-lowering effects of repaglinide. Adding itraconazole to repaglinide and gemfibrozil therapy resulted in even higher repaglinide levels.
Medscape Pharmacists. 2003;4(2) © 2003 Medscape
Cite this: October 2003 - Medscape - Oct 22, 2003.